Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study by Pujol, Jean-Louis, MD, PhD, Vansteenkiste, Johan, MD, PhD, Paz-Ares Rodríguez, Luis, MD, PhD, Gregorc, Vanesa, MD, Mazieres, Julien, MD, PhD, Awad, Mark, MD, PhD, Jänne, Pasi A., MD, PhD, Chisamore, Michael, PhD, Hossain, Anwar M., MStat, Chen, Yanyun, PhD, Beck, J. Thaddeus, MD, FACP

Get full text

Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial by Wolf, Jürgen, MD, Hochmair, Maximilian, MD, Han, Ji-Youn, MD PhD, Reguart, Noemi, MD PhD, Souquet, Pierre-Jean, MD, Smit, Egbert F, MD PhD, Orlov, Sergey V, MD PhD, Vansteenkiste, Johan, MD PhD, Nishio, Makoto, MD PhD, de Jonge, Maja, MD PhD, Akerley, Wallace, MD, Garon, Edward B, MD, Groen, Harry J M, MD PhD, Tan, Daniel S W, MD PhD, Seto, Takashi, MD, Frampton, Garrett M, PhD, Robeva, Anna, MS, Carbini, Mariana, MD, Le Mouhaer, Sylvie, MSc, Yovine, Alejandro, MD, Boran, Aislyn, PhD, Bossen, Claudia, PhD, Yang, Yiqun, PhD, Ji, Lexiang, PhD, Fairchild, Lauren, PhD, Heist, Rebecca S, MD

Get full text

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC by Vansteenkiste, Johan F., Naidoo, Jarushka, Faivre-Finn, Corinne, Özgüroğlu, Mustafa, Villegas, Augusto, Daniel, Davey, Murakami, Shuji, Hui, Rina, Lee, Ki Hyeong, Cho, Byoung Chul, Kubota, Kaoru, Broadhurst, Helen, Wadsworth, Catherine, Newton, Michael, Thiyagarajah, Piruntha, Antonia, Scott J.

Get full text

Symptomatic Pneumonitis with Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer by Vansteenkiste, Johan F., MD, PhD, Naidoo, Jarushka, MB, BCH, MHS, Faivre–Finn, Corinne, MD, PhD, Özgüroğlu, Mustafa, MD, Villegas, Augusto, MD, Daniel, Davey, MD, Murakami, Shuji, MD, Hui, Rina, MBBS, PhD, Lee, Ki Hyeong, MD, Cho, Byoung Chul, MD, PhD, Kubota, Kaoru, MD, PhD, Broadhurst, Helen, MSc, Wadsworth, Catherine, BVSc, Newton, Michael, PharmD, Thiyagarajah, Piruntha, MD, Antonia, Scott J., MD

Get full text

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, pla... by Vansteenkiste, Johan F, Prof Dr, Cho, Byoung Chul, MD, Vanakesa, Tonu, MD, De Pas, Tommaso, MD, Zielinski, Marcin, Prof, Kim, Moon Soo, MD, Jassem, Jacek, Prof, Yoshimura, Masahiro, MD, Dahabreh, Jubrail, MD, Nakayama, Haruhiku, MD, Havel, Libor, MD, Kondo, Haruhiko, MD, Mitsudomi, Tetsuya, Prof, Zarogoulidis, Konstantinos, Prof, Gladkov, Oleg A, MD, Udud, Katalin, MD, Tada, Hirohito, MD, Hoffman, Hans, Prof, Bugge, Anders, MD, Taylor, Paul, MD, Gonzalez, Emilio Esteban, Prof, Liao, Mei Lin, Prof, He, Jianxing, MD, Pujol, Jean-Louis, Prof, Louahed, Jamila, PhD, Debois, Muriel, MSc, Brichard, Vincent, MD, Debruyne, Channa, MD, Therasse, Patrick, MD, Altorki, Nasser, MD

Get full text

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial by Fehrenbacher, Louis, Dr, Spira, Alexander, MD, Ballinger, Marcus, PhD, Kowanetz, Marcin, PhD, Vansteenkiste, Johan, Prof, Mazieres, Julien, Prof, Park, Keunchil, Prof, Smith, David, MD, Artal-Cortes, Angel, MD, Lewanski, Conrad, MD, Braiteh, Fadi, MD, Waterkamp, Daniel, MD, He, Pei, PhD, Zou, Wei, PhD, Chen, Daniel S, MD, Yi, Jing, PhD, Sandler, Alan, MD, Rittmeyer, Achim, MD

Get full text

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study by Barlesi, Fabrice, Prof, Vansteenkiste, Johan, Prof, Spigel, David, MD, Ishii, Hidenobu, MD, Garassino, Marina, MD, de Marinis, Filippo, MD, Özgüroğlu, Mustafa, Prof, Szczesna, Aleksandra, MD, Polychronis, Andreas, PhD, Uslu, Ruchan, MD, Krzakowski, Maciej, Prof, Lee, Jong-Seok, Prof, Calabrò, Luana, MD, Arén Frontera, Osvaldo, MD, Ellers-Lenz, Barbara, MS, Bajars, Marcis, MD, Ruisi, Mary, MD, Park, Keunchil, Prof

Get full text

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial by Kim, Dong-Wan, MD, Mehra, Ranee, MD, Tan, Daniel S W, MD, Felip, Enriqueta, MD, Chow, Laura Q M, MD, Camidge, D Ross, Prof, Vansteenkiste, Johan, Prof, Sharma, Sunil, Prof, De Pas, Tommaso, MD, Riely, Gregory J, MD, Solomon, Benjamin J, MBBS, Wolf, Jürgen, Prof, Thomas, Michael, Prof, Schuler, Martin, Prof, Liu, Geoffrey, MD, Santoro, Armando, Prof, Sutradhar, Santosh, PhD, Li, Siyu, PhD, Szczudlo, Tomasz, MD, Yovine, Alejandro, MD, Shaw, Alice T, Dr

Get full text

Selumetinib plus docetaxel for KRAS -mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study by Jänne, Pasi A, Dr, Shaw, Alice T, MD, Pereira, José Rodrigues, MD, Jeannin, Gaëlle, MD, Vansteenkiste, Johan, Prof, Barrios, Carlos, MD, Franke, Fabio Andre, MD, Grinsted, Lynda, MSc, Zazulina, Victoria, MD, Smith, Paul, PhD, Smith, Ian, MD, Crinò, Lucio, Prof

Get full text